IPO in June 2021 (NASDAQ: CVRX).

CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. The Barostim neo™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. The Barostim neo can be adjusted to meet each patient’s individual therapy needs.